Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome
Neonatal Network · 2025
DOI: 10.1891/nn-2024-0059 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neonatal Network, 2025. Verfasst von Susan Givens Bell. Hauptthemen laut MEDLINE: Neonatal Abstinence Syndrome, Clonidine, Phenobarbital, Analgesics, Opioid. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Nonpharmacologic management is the first-line therapy for infants experiencing neonatal opioid withdrawal syndrome (NOWS) and/or neonatal abstinence syndrome (NAS). Currently, the most prescribed first-line pharmacologic agent is an opioid, most often morphine, but methadone and buprenorphine are preferred by some providers. For some infants, an opioid, along with maximized nonpharmacologic strategies, does not provide adequate symptom relief and a second-line agent is needed. Phenobarbital and clonidine are two commonly prescribed second-line agents for the management of NOWS/NAS. This column will describe these two commonly prescribed second-line agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Bell, S. G. (2025). Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome. Neonatal Network. https://doi.org/10.1891/nn-2024-0059
Vancouver
Bell SG. Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome. Neonatal Network. 2025. doi:10.1891/nn-2024-0059
BibTeX
@article{Bell2025,
author = {Bell, Susan Givens},
title = {Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome},
journal = {Neonatal Network},
year = {2025},
doi = {10.1891/nn-2024-0059}
}
EUVIMED